Drug Profile
Megadose drug combination - Cell Source
Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Cell Source
- Developer The University of Parma
- Class Stem cell therapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bone marrow transplant rejection
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for phase-I development in Bone-marrow-transplant-rejection in Italy (IV, Infusion)
- 11 Nov 2015 Cell Source plans a phase I/II trial in Transplant rejection in Germany and Italy
- 01 Jul 2015 Phase I trials in Bone marrow transplant rejection in Italy (IV)